Benefit vs cost: ASCO unveils cancer drug 'value' tool
This article was originally published in Scrip
Executive Summary
The American Society of Clinical Oncology (ASCO) asked the question "What is a cancer drug's true value?" and in four very specific treatment situations the organization's Value in Cancer Care Task Force supplied an answer: It depends.
You may also be interested in...
Oncology Is Booming But Cost Outlook Is Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.